Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
The recent success of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), has revolutionised the field of obesity treatment
When you join the Academy, youll get access to tools and coaching that help you: Shift your mindset around food and weight loss Deal with emotional eating and find new coping mechanisms Recognize and manage lower brain chatterthose automatic thoughts that can sabotage your progress Discover joy in activities that arent centered around food Join the Half-Size Me Academy today to get the mindset support you need
If your Cigna plan covers Wegovy, the manufacturer savings card can be used alongside your insurance to reduce your out-of-pocket costs further
Clinical trials demonstrate: Weeks 14 : Minimal weight loss as your body adjusts Months 23 : More noticeable weight reduction as dose escalation continues Months 46 : Steady, consistent weight loss Peak effect : Maximum weight loss typically occurs at 6068 weeks of continuous treatment [15] According to FDA-approved labeling, patients on Wegovy (2.4 mg weekly) lost an average of 15% of their body weight over 68 weeks in clinical trials (STEP 1)
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has a slightly different receptor activity profile and may be tolerated differently, though gastrointestinal side effects remain common
